Akiyoshi Takami

Prof. Akiyoshi Takami

Aichi Medical University, Nagakute, Japan
orcid

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 May 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
RKRitesh Kotecha
Ritesh Kotecha
Akiyoshi TakamiAkiyoshi Takami
Akiyoshi Takami
Luis EspinozaLuis Espinoza
Luis Espinoza
Dietary phytochemicals and cancer chemoprevention: a review of the clinical evidence

15 February 2006 in Blood
Verified
Journal Article
Open access
PDF file
CSChiharu Sugimori
Chiharu Sugimori
TCTatsuya Chuhjo
Tatsuya Chuhjo
XFXingmin Feng
Xingmin Feng
HYHirohito Yamazaki
Hirohito Yamazaki
Akiyoshi TakamiAkiyoshi Takami
Akiyoshi Takami
SNShinji Nakao
Shinji Nakao
We investigated the clinical significance of a minor population of paroxysmal nocturnal hemoglobinuria (PNH)-type blood cells in patients with acquired aplastic anemia (AA). We quantified CD55-CD59- granulocytes and red blood cells (RBCs) in peripheral blood from 122 patients with recently diagnosed AA and correlated numbers of PNH-type cells and responses to immunosuppressive therapy (IST). Flow cytometry detected 0.005% to 23.1% of GPI-AP- cells in 68% of patients with AA. Sixty-eight of 83 (91%) patients with an increased proportion of PNH-type cells (PNH+) responded to antithymocyte globulin (ATG) + cyclosporin (CsA) therapy, whereas 18 of 39 (48%) without such an increase (PNH-) responded. Failure-free survival rates were significantly higher (64%) among patients with PNH+ than patients with PNH- (12%) at 5 years, although overall survival rates were comparable between the groups. Numbers of PNH-type and normal-type cells increased in parallel among most patients with PNH+ who responded to IST, suggesting that these cells are equally sensitive to immune attack. These results indicate that a minor population of PNH-type cells represents a reliable marker of a positive IST response and a favorable prognosis among patients with AA. Furthermore, immune attack against hematopoietic stem cells that allows PNH clonal expansion might occur only at the onset of AA.

20 October 2011 in PLOS ONE
Verified
Journal Article
Open access
PDF file
Luis EspinozaLuis Espinoza
Luis Espinoza
Akiyoshi TakamiAkiyoshi Takami
Akiyoshi Takami
KNKatsuya Nakata
Katsuya Nakata
MOMakoto Onizuka
Makoto Onizuka
TKTakakazu Kawase
Takakazu Kawase
FPFor The Japan Marrow Donor Program
For The Japan Marrow Donor Program
Interleukin IL-17 is a proinflammatory cytokine that has been implicated in the pathogenesis of various autoimmune diseases. The single nucleotide polymorphism (SNP), rs2275913, in the promoter region of the IL-17 gene is associated with susceptibility to ulcerative colitis. When we examined the impact of rs2275913 in a cohort consisting of 438 pairs of patients and their unrelated donors transplanted through the Japan Marrow Donor Program, the donor IL-17 197A allele was found to be associated with a higher risk of acute graft-versus-host disease (GVHD; hazard ratio [HR], 1.46; 95% confidence interval [CI], 1.00 to 2.13; P = 0.05). Next, we investigated the functional relevance of the rs2275913 SNP. In vitro stimulated T cells from healthy individuals possessing the 197A allele produced significantly more IL-17 than those without the 197A allele. In a gene reporter assay, the 197A allele construct induced higher luciferase activity than the 197G allele, and the difference was higher in the presence of T cell receptor activation and was abrogated by cyclosporine treatment. Moreover, the 197A allele displayed a higher affinity for the nuclear factor activated T cells (NFAT), a critical transcription factor involved in IL-17 regulation. These findings substantiate the functional relevance of the rs2275913 polymorphism and indicate that the higher IL-17 secretion by individuals with the 197A allele likely accounts for their increased risk for acute GVHD and certain autoimmune diseases.

25 January 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
LTLy Quoc Trung
Ly Quoc Trung
Luis EspinozaLuis Espinoza
Luis Espinoza
Akiyoshi TakamiAkiyoshi Takami
Akiyoshi Takami
SNShinji Nakao
Shinji Nakao
Natural killer (NK) cell malignancies, particularly aggressive NK cell leukaemias and lymphomas, have poor prognoses. Although recent regimens with L-asparaginase substantially improved outcomes, novel therapeutic approaches are still needed to enhance clinical response. Resveratrol, a naturally occurring polyphenol, has been extensively studied for its anti-inflammatory, cardioprotective and anti-cancer activities. In this study, we investigated the potential anti-tumour activities of resveratrol against the NK cell lines KHYG-1, NKL, NK-92 and NK-YS. Resveratrol induced robust G0/G1 cell cycle arrest, significantly suppressed cell proliferation and induced apoptosis in a dose- and time-dependent manner for all four cell lines. In addition, resveratrol suppressed constitutively active STAT3 in all the cell lines and inhibited JAK2 phosphorylation but had no effect on other upstream mediators of STAT3 activation, such as PTEN, TYK2, and JAK1. Resveratrol also induced downregulation of the anti-apoptotic proteins MCL1 and survivin, two downstream effectors of the STAT3 pathway. Finally, resveratrol induced synergistic effect on the apoptotic and antiproliferative activities of L-asparaginase against KHYG-1, NKL and NK-92 cells. These results suggest that resveratrol may have therapeutic potential against NK cell malignancies. Furthermore, our finding that resveratrol is a bonafide JAK2 inhibitor extends its potential benefits to other diseases with dysregulated JAK2 signaling.

27 January 2018 in International Journal of Hematology
Verified
Journal Article
Closed access
PDF file
Akiyoshi TakamiAkiyoshi Takami
Akiyoshi Takami

4 April 2012 in Haematologica
Verified
Journal Article
Closed access
PDF file
Luis EspinozaLuis Espinoza
Luis Espinoza
Akiyoshi TakamiAkiyoshi Takami
Akiyoshi Takami
KYK. Yoshioka
K. Yoshioka
KNK. Nakata
K. Nakata
TST. Sato
T. Sato
SNS. Nakao
S. Nakao
Background NKG2D is an activating receptor expressed by natural killer and T cells, which have crucial functions in tumor and microbial immunosurveillance. Several cytokines have been identified as modulators of NKG2D receptor expression. However, little is known about NKG2D gene regulation. In this study, we found that microRNA 1245 attenuated the expression of NKG2D in natural killer cells. Design and Methods We investigated the potential interactions between the 3′-untranslated region of the NKG2D gene and microRNA as well as their functional roles in the regulation of NKG2D expression and cytotoxicity in natural killer cells. Results Transforming growth factor-β1, a major negative regulator of NKG2D expression, post-transcriptionally up-regulated mature microRNA-1245 expression, thus down-regulating NKG2D expression and impairing NKG2D-mediated immune responses in natural killer cells. Conversely, microRNA-1245 down-regulation significantly increased the expression of NKG2D expression in natural killer cells, resulting in more efficient NKG2D-mediated cytotoxicity. Conclusions These results reveal a novel NKG2D regulatory pathway mediated by microRNA-1245, which may represent one of the mechanisms used by transforming growth factor-β1 to attenuate NKG2D expression in natural killer cells.